| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. | Crit Care Med | 2003 | 2.54 |
| 2 | Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. | Pediatrics | 2004 | 1.60 |
| 3 | Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. | Am J Surg | 2004 | 0.92 |
| 4 | CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. | J Intensive Care Med | 2011 | 0.85 |
| 5 | Static and dynamic assessment of biomarkers in surgical patients with severe sepsis. | Surg Infect (Larchmt) | 2004 | 0.79 |
| 6 | Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis. | Surg Infect (Larchmt) | 2004 | 0.78 |